Cutaneous Adverse Reactions to Apalutamide: Case Series with Clinical and Pathological Correlations
DOI:
https://doi.org/10.2340/actadv.v104.40719Keywords:
apalutamide, severe cutaneous reactions, scars, drug adverse reactions, prostate cancerAbstract
Abstract is missing (Short communication)
Downloads
References
Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, et al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2018; 19: 1404-1416.
https://doi.org/10.1016/S1470-2045(18)30456-X DOI: https://doi.org/10.1016/S1470-2045(18)30456-X
Uemura H, Arai G, Uemura H, Suzuki H, Aoyama J, Hatayama T, et al. Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study. Int J Urol 2022; 29: 533-540.
https://doi.org/10.1111/iju.14843 DOI: https://doi.org/10.1111/iju.14843
Uemura H, Koroki Y, Iwaki Y, Imanaka K, Kambara T, Lopez-Gitlitz A, et al. Skin rash following administration of apalutamide in Japanese patients with advanced prostate cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study. BMC Urol 2020; 20: 139.
https://doi.org/10.1186/s12894-020-00689-0 DOI: https://doi.org/10.1186/s12894-020-00689-0
Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, et al. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol 2019; 20: 1518-1530.
https://doi.org/10.1016/S1470-2045(19)30620-5 DOI: https://doi.org/10.1016/S1470-2045(19)30620-5
Katsuta M, Kimura T, Tashiro K, Murakami M, Hata K, Yanagisawa T, et al. Low body weight as a risk factor for apalutamide-related cutaneous adverse events. Anticancer Res 2022; 42: 2023-2028.
https://doi.org/10.21873/anticanres.15682 DOI: https://doi.org/10.21873/anticanres.15682
Tohi Y, Kato T, Fukuhara H, Kobayashi K, Ohira S, Ikeda K, et al. Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium. Int J Clin Oncol 2022; 27: 1348-1355.
https://doi.org/10.1007/s10147-022-02183-z DOI: https://doi.org/10.1007/s10147-022-02183-z
Katsuta M, Nobeyama Y, Hirafuku K, Tashiro K, Kimura T, Asahina A. Characteristics of mild and severe apalutamide-related cutaneous adverse events in patients with prostate cancer: s review of the literature. J Dermatol 2024; 51: 110-114.
https://doi.org/10.1111/1346-8138.16972 DOI: https://doi.org/10.1111/1346-8138.16972
Ducharme O, Sanchez-Pena P, Pham-Ledard A, Beylot-Barry M, Milpied B. The first case of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome caused by apalutamide, a novel oral androgen receptor antagonist. Contact Dermatitis 2022; 86: 313-315.
https://doi.org/10.1111/cod.14024 DOI: https://doi.org/10.1111/cod.14024
Hsu YSO, Hsieh TS, Huang PW, Chu CY. Drug reaction with eosinophilia and systemic symptoms with features resembling Stevens-Johnson syndrome/toxic epidermal necrolysis related to apalutamide. J Eur Acad Dermatol Venereol 2023; 37: 246-248.
https://doi.org/10.1111/jdv.18660 DOI: https://doi.org/10.1111/jdv.18660
Huang Y, Luo J, Luo J, Leng Y, Han Q, Wen J, et al. Toxic epidermal necrolysis associated with apalutamide: a case report and brief review of the literature. 2022 [cited 2023 Mar 22]. Available from: https://doi.org/10.22541/au.165392104.40579095/v1
https://doi.org/10.22541/au.165392104.40579095/v1 DOI: https://doi.org/10.22541/au.165392104.40579095/v1
Honda T, Tohi Y, Kaku Y, Kimura N, Kato T, Haba R, et al. Acute generalized exanthematous pustulosis during apalutamide treatment in a patient with prostate cancer. IJU Case Rep 2022; 5: 497-500.
https://doi.org/10.1002/iju5.12525 DOI: https://doi.org/10.1002/iju5.12525
Kawakami Y, Mitsui M, Takamoto H, Yamamoto Y. Apalutamide-induced exanthematous drug eruption displaying spongiotic dermatitis successfully treated with dose reduction. Int J Dermatol 2021; 60: 315-317.
https://doi.org/10.1111/ijd.15420 DOI: https://doi.org/10.1111/ijd.15420
Cremante M, Puglisi S, Gandini A, Guadagno A, Catalano F, Damassi A, et al. Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer. J Oncol Pharm Pract 2023; 29: 1748-1753.
https://doi.org/10.1177/10781552231180598 DOI: https://doi.org/10.1177/10781552231180598
T'jollyn H, Ackaert O, Chien C, Lopez-Gitlitz A, McCarthy S, Ruixo CP, et al. Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study. Cancer Chemother Pharmacol 2022; 89: 629-641.
https://doi.org/10.1007/s00280-022-04427-1 DOI: https://doi.org/10.1007/s00280-022-04427-1
Saito-Sasaki N, Sawada Y, Okada E, Nakamura M. Drug eruption caused by enzalutamide: a case and literature review of androgen receptor inhibitor-related drug eruptions. Australas J Dermatol 2018; 59: 133-134.
https://doi.org/10.1111/ajd.12694 DOI: https://doi.org/10.1111/ajd.12694
Ji C, Guha M, Zhu X, Whritenour J, Hemkens M, Tse S, et al. Enzalutamide and apalutamide: in vitro chemical reactivity studies and activity in a mouse drug allergy model. Chem Res Toxicol 2020; 33: 211-222.
https://doi.org/10.1021/acs.chemrestox.9b00247 DOI: https://doi.org/10.1021/acs.chemrestox.9b00247
Oishi T, Hatakeyama S, Tabata R, Fujimori D, Kawashima Y, Tanaka R, et al. Effects of apalutamide dose reduction on skin-related adverse events in patients with advanced prostate cancer: a multicenter retrospective study. Prostate 2023; 83: 198-203.
https://doi.org/10.1002/pros.24453 DOI: https://doi.org/10.1002/pros.24453
Yu Z, Yu K, Lv S, Wen, H, Fang W. Titration as an effective strategy to reduce apalutamide induced skin rash: a multi-institutional real-world experience. J Clin Oncol 2023; 41: 197-197.
https://doi.org/10.1200/JCO.2023.41.6_suppl.197 DOI: https://doi.org/10.1200/JCO.2023.41.6_suppl.197
Downloads
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Javier Gil-Lianes, Victoria Amat-Samaranch, Priscila Giavedoni, Antoni Vilaseca, Julián Córdoba Sánchez, Francesc Alamon-Reig, Paola Castillo, Adriana P. Garcia, Mariona Pascal, Cristina Carrera
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
